Tacrine (CAS 321-64-2): A Historical Perspective in Alzheimer's Treatment
Tacrine, identified by CAS number 321-64-2, represents a significant milestone in the historical treatment of Alzheimer's disease. As one of the first centrally acting cholinesterase inhibitors to be approved, it paved the way for future advancements in managing cognitive impairment associated with this neurodegenerative condition.
Developed with the aim of increasing acetylcholine levels in the brain—a neurotransmitter crucial for memory and learning—Tacrine offered a new therapeutic avenue. Its mechanism involved inhibiting the enzyme acetylcholinesterase, thus preventing the rapid breakdown of acetylcholine. This intervention was intended to improve cholinergic neurotransmission and, consequently, cognitive function in patients. Its chemical structure, C13H14N2, is characteristic of the acridine class of compounds.
However, the clinical journey of Tacrine was marked by challenges. While demonstrating some efficacy, it was associated with considerable side effects, most notably hepatotoxicity, which led to its eventual discontinuation in many therapeutic contexts. This led to the search for safer and more tolerable alternatives, a pursuit that has yielded newer generations of cholinesterase inhibitors.
For researchers and scientists, Tacrine remains a compound of interest for historical context and comparative pharmacological studies. If you are involved in research related to neurodegenerative diseases or drug development history, obtaining Tacrine (CAS 321-64-2) from reliable sources is important. Engaging with established tacrine manufacturers in China can provide access to this historically significant chemical. Understanding the tacrine price FOB China can assist in project planning for research involving this compound, including studies of acetylcholinesterase inhibitor Tacrine.
The legacy of Tacrine underscores the evolution of treatments for Alzheimer's disease and highlights the ongoing importance of chemical research in developing effective therapeutic agents. By studying compounds like Tacrine, we gain deeper insights into disease mechanisms and the principles of drug design.
Developed with the aim of increasing acetylcholine levels in the brain—a neurotransmitter crucial for memory and learning—Tacrine offered a new therapeutic avenue. Its mechanism involved inhibiting the enzyme acetylcholinesterase, thus preventing the rapid breakdown of acetylcholine. This intervention was intended to improve cholinergic neurotransmission and, consequently, cognitive function in patients. Its chemical structure, C13H14N2, is characteristic of the acridine class of compounds.
However, the clinical journey of Tacrine was marked by challenges. While demonstrating some efficacy, it was associated with considerable side effects, most notably hepatotoxicity, which led to its eventual discontinuation in many therapeutic contexts. This led to the search for safer and more tolerable alternatives, a pursuit that has yielded newer generations of cholinesterase inhibitors.
For researchers and scientists, Tacrine remains a compound of interest for historical context and comparative pharmacological studies. If you are involved in research related to neurodegenerative diseases or drug development history, obtaining Tacrine (CAS 321-64-2) from reliable sources is important. Engaging with established tacrine manufacturers in China can provide access to this historically significant chemical. Understanding the tacrine price FOB China can assist in project planning for research involving this compound, including studies of acetylcholinesterase inhibitor Tacrine.
The legacy of Tacrine underscores the evolution of treatments for Alzheimer's disease and highlights the ongoing importance of chemical research in developing effective therapeutic agents. By studying compounds like Tacrine, we gain deeper insights into disease mechanisms and the principles of drug design.
Perspectives & Insights
Future Origin 2025
“Its chemical structure, C13H14N2, is characteristic of the acridine class of compounds.”
Core Analyst 01
“While demonstrating some efficacy, it was associated with considerable side effects, most notably hepatotoxicity, which led to its eventual discontinuation in many therapeutic contexts.”
Silicon Seeker One
“This led to the search for safer and more tolerable alternatives, a pursuit that has yielded newer generations of cholinesterase inhibitors.”